Psychopharmacology

, Volume 233, Issue 5, pp 823–829 | Cite as

Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities

  • Joaquim Soler
  • Matilde Elices
  • Alba Franquesa
  • Steven Barker
  • Pablo Friedlander
  • Amanda Feilding
  • Juan C. Pascual
  • Jordi Riba
Original Investigation

Abstract

Background

Ayahuasca is a psychotropic plant tea used for ritual purposes by the indigenous populations of the Amazon. In the last two decades, its use has expanded worldwide. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine-oxidase-inhibiting properties. Acute administration induces an introspective dream-like experience characterized by visions and autobiographic and emotional memories. Studies of long-term users have suggested its therapeutic potential, reporting that its use has helped individuals abandon the consumption of addictive drugs. Furthermore, recent open-label studies in patients with treatment-resistant depression found that a single ayahuasca dose induced a rapid antidepressant effect that was maintained weeks after administration. Here, we conducted an exploratory study of the psychological mechanisms that could underlie the beneficial effects of ayahuasca.

Methods

We assessed a group of 25 individuals before and 24 h after an ayahuasca session using two instruments designed to measure mindfulness capacities: The Five Facets Mindfulness Questionnaire (FFMQ) and the Experiences Questionnaire (EQ).

Results

Ayahuasca intake led to significant increases in two facets of the FFMQ indicating a reduction in judgmental processing of experiences and in inner reactivity. It also led to a significant increase in decentering ability as measured by the EQ. These changes are classic goals of conventional mindfulness training, and the scores obtained are in the range of those observed after extensive mindfulness practice.

Conclusions

The present findings support the claim that ayahuasca has therapeutic potential and suggest that this potential is due to an increase in mindfulness capacities.

Keywords

Ayahuasca Therapeutic potential Mindfulness Decentering Human 

References

  1. Baer RA, Smith GT, Hopkins J et al (2006) Using self-report assessment methods to explore facets of mindfulness. Assessment 13:27–45CrossRefPubMedGoogle Scholar
  2. Bishop SR, Lau M, Shapiro S et al (2004) Mindfulness: a proposed operational definition. Clin Psychol Sci Pract 11:230–241CrossRefGoogle Scholar
  3. Bliss S, McCardle M (2013) An exploration of common elements in dialectical behavior therapy, mentalization based treatment and transference focused psychotherapy in the treatment of borderline personality disorder. Clin Soc Work J 42:61–69CrossRefGoogle Scholar
  4. Bouso JC, González D, Fondevila S et al (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. PLoS One 7:e42421PubMedCentralCrossRefPubMedGoogle Scholar
  5. Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A et al (2015) Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol 25:483–492CrossRefPubMedGoogle Scholar
  6. Brown KW, Ryan RM (2003) The benefits of being present: mindfulness and its role in psychological well-being. J Pers Soc Psychol 84:822–848CrossRefPubMedGoogle Scholar
  7. Buckholtz NS, Boggan WO (1977a) Monoamine oxidase inhibition in brain and liver produced by beta-carbolines: structure-activity relationships and substrate specificity. Biochem Pharmacol 26:1991–1996CrossRefPubMedGoogle Scholar
  8. Buckholtz NS, Boggan WO (1977b) Inhibition by beta-carbolines of monoamine uptake into a synaptosomal preparation: structure-activity relationships. Life Sci 20:2093–2099CrossRefPubMedGoogle Scholar
  9. Carmody J, Baer RA, Lykins ELB, Olendzki N (2009) An empirical study of the mechanisms of mindfulness in a mindfulness-based stress reduction program. J Clin Psychol 65:613–626CrossRefPubMedGoogle Scholar
  10. Cebolla A, Garcia Palacios A, Soler J et al (2012) Psychometric properties of the Spanish validation of the Five Facets of Mindfulness Questionnaire (FFMQ). Eur J Psychiatry 26:118–126.CrossRefGoogle Scholar
  11. Coffey KA, Hartman M, Fredrickson BL (2010) Deconstructing mindfulness and constructing mental health: understanding mindfulness and its mechanisms of action. Mindfulness 1:235–253CrossRefGoogle Scholar
  12. Fábregas JM, González D, Fondevila S et al (2010) Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend 111:257–261CrossRefPubMedGoogle Scholar
  13. Foa EB, Riggs DS, Massie ED, Yarczower M (1995) The impact of fear activation and anger on the efficacy of exposure treatment for posttraumatic stress disorder. Behav Ther 26:487–499CrossRefGoogle Scholar
  14. Fontanilla D, Johannessen M, Hajipour AR et al (2009) The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323:934–937PubMedCentralCrossRefPubMedGoogle Scholar
  15. Fresco DM, Moore MT, van Dulmen MHM et al (2007a) Initial psychometric properties of the experiences questionnaire: validation of a self-report measure of decentering. Behav Ther 38:234–246CrossRefPubMedGoogle Scholar
  16. Fresco DM, Segal ZV, Buis T, Kennedy S (2007b) Relationship of posttreatment decentering and cognitive reactivity to relapse in major depression. J Consult Clin Psychol 75:447–455CrossRefPubMedGoogle Scholar
  17. Frood A (2015) Ayahuasca psychedelic tested for depression. Nature. doi:10.1038/nature.2015.17252 Google Scholar
  18. Gasser P, Holstein D, Michel Y et al (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513–520PubMedCentralCrossRefPubMedGoogle Scholar
  19. Grob CS, Danforth AL, Chopra GS et al (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71–78CrossRefPubMedGoogle Scholar
  20. Grossman P (2008) On measuring mindfulness in psychosomatic and psychological research. J Psychosom Res 64:405–408CrossRefPubMedGoogle Scholar
  21. Grossman P (2011) Defining mindfulness by how poorly I think I pay attention during everyday awareness and other intractable problems for psychology’s (re)invention of mindfulness: comment on Brown et al. (2011). Psychol Assess 23:1034–1040, discussion 1041–1046CrossRefPubMedGoogle Scholar
  22. Hayes-skelton SA, Calloway A, Roemer L, Orsillo SM (2014) Decentering as a potential common mechanism across two therapies for generalized anxiety disorder. J Consult Clin Psychol 83:395–404CrossRefPubMedGoogle Scholar
  23. Holzel BK, Lazar SW, Gard T et al (2011) How does mindfulness meditation work? Proposing mechanisms of action from a conceptual and neural perspective. Perspect Psychol Sci 6:537–559CrossRefPubMedGoogle Scholar
  24. Kabat-Zinn J (1990) Full catastrophe living: using the wisdom of your body and mind to face stress, pain, and illness. Delacorte, New YorkGoogle Scholar
  25. Kraehenmann R, Preller KH, Scheidegger M et al (2014) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol PsychiatryGoogle Scholar
  26. Lilja JL, Lundh L-G, Josefsson T, Falkenström F (2012) Observing as an essential facet of mindfulness: a comparison of FFMQ patterns in meditating and non-meditating individuals. Mindfulness 4:203–212CrossRefGoogle Scholar
  27. McIlhenny EH, Pipkin KE, Standish LJ et al (2009) Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr A 1216:8960–8968CrossRefPubMedGoogle Scholar
  28. McKenna DJ, Towers GN, Abbott F (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca. J Ethnopharmacol 10:195–223CrossRefPubMedGoogle Scholar
  29. Osório F de L, Sanches RF, Macedo LR (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr São Paulo Braz 37:13–20CrossRefGoogle Scholar
  30. Pezawas L, Meyer-Lindenberg A, Drabant EM et al (2005) 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 8:828–834CrossRefPubMedGoogle Scholar
  31. Raichle ME, MacLeod AM, Snyder AZ et al (2001) A default mode of brain function. Proc Natl Acad Sci U S A 98:676–682PubMedCentralCrossRefPubMedGoogle Scholar
  32. Riba J (2003) Human pharmacology of ayahuasca. Autonomous University of BarcelonaGoogle Scholar
  33. Riba J, Rodríguez-Fornells A, Urbano G et al (2001) Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl) 154:85–95CrossRefGoogle Scholar
  34. Riba J, Romero S, Grasa E et al (2006) Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl) 186:93–98CrossRefGoogle Scholar
  35. Riba J, McIlhenny EH, Bouso JC, Barker SA (2015) Metabolism and urinary disposition of N, N-dimethyltryptamine after oral and smoked administration: a comparative study. Drug Test Anal 7:401–406CrossRefPubMedGoogle Scholar
  36. Rivier L, Lindgren JE (1972) “Ayahuasca”, the South American hallucinogenic drink: an ethnobotanical and chemical investigation. Econ Bot 26:101–129CrossRefGoogle Scholar
  37. Sanches RF, Osório FL, dos Santos RG et al (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol in pressGoogle Scholar
  38. Santos RG, Landeira-Fernandez J, Strassman RJ et al (2007) Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol 112:507–513CrossRefPubMedGoogle Scholar
  39. Schultes RE (1980) The botany and chemistry of hallucinogens, Rev. and enl. 2d ed. Thomas, SpringfieldGoogle Scholar
  40. Segal ZV, Kennedy S, Gemar M et al (2006) Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. Arch Gen Psychiatry 63:749–755CrossRefPubMedGoogle Scholar
  41. Sessa B, Johnson MW (2015) Can psychedelic compounds play a part in drug dependence therapy? Br J Psychiatry 206:1–3CrossRefPubMedGoogle Scholar
  42. Shanon B (2002) The antipodes of the mind: charting the phenomenology of the Ayahuasca experience. Oxford University Press, OxfordGoogle Scholar
  43. Shapiro S, Carlson LE, Astin J, Freedman B (2006) Mechanisms of mindfulness. J Clin Psychol 62:373–386CrossRefPubMedGoogle Scholar
  44. Sheline YI, Price JL, Yan Z, Mintun MA (2010) Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci U S A 107:11020–11025PubMedCentralCrossRefPubMedGoogle Scholar
  45. Soler J, Cebolla A, Feliu-Soler A et al (2014a) Relationship between meditative practice and self-reported mindfulness: the MINDSENS composite index. PLoS ONE 9:e86622PubMedCentralCrossRefPubMedGoogle Scholar
  46. Soler J, Franquesa A, Feliu-Soler A et al (2014b) Assesing decentering: validation, psychometric properities and clinical usefulness of the Experiences Questionnaire in a Spanish sample. Behav Ther 45:863–871CrossRefPubMedGoogle Scholar
  47. Suzuki O, Katsumata Y, Oya M (1981) Characterization of eight biogenic indoleamines as substrates for type A and type B monoamine oxidase. Biochem Pharmacol 30:1353–1358CrossRefPubMedGoogle Scholar
  48. Taylor A, Grant J, Breton E et al (2013) Impact of meditation training on the default mode network during a restful state. 4–14Google Scholar
  49. Teasdale JD, Moore R, Hayhurst H et al (2002) Metacognitive awareness and prevention of relapse in depression: empirical evidence. J Consult Clin Psychol 70:275–287CrossRefPubMedGoogle Scholar
  50. Tejedor R, Feliu-Soler A, Pascual JC et al (2014) Propiedades psicométricas de la versión española de la Philadelphia Mindfulness Scale. Rev Psiquiatr Salud Ment 7:157–165CrossRefPubMedGoogle Scholar
  51. Thomas G, Lucas P, Capler NR et al (2013) Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev 6:30–42CrossRefPubMedGoogle Scholar
  52. Tupper KW (2008) The globalization of ayahuasca: harm reduction or benefit maximization? Int J Drug Policy 19:297–303CrossRefPubMedGoogle Scholar
  53. Veehof MM, Peter M, Taal E et al (2011) Psychometric properties of the Dutch Five Facet Mindfulness Questionnaire (FFMQ) in patients with fibromyalgia. Clin Rheumatol 30:1045–1054PubMedCentralCrossRefPubMedGoogle Scholar
  54. Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642–651CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Joaquim Soler
    • 1
    • 2
    • 3
  • Matilde Elices
    • 1
    • 3
    • 4
    • 5
  • Alba Franquesa
    • 4
    • 6
  • Steven Barker
    • 7
  • Pablo Friedlander
    • 8
  • Amanda Feilding
    • 8
  • Juan C. Pascual
    • 1
    • 3
    • 4
  • Jordi Riba
    • 3
    • 9
    • 10
    • 11
  1. 1.Servei de Psiquiatria, Hospital de la Santa Creu i Sant Pau (Barcelona)Universitat Autònoma de Barcelona (UAB)BarcelonaSpain
  2. 2.Departamento de Psicologia Clínica i de la SalutUniversitat Autònoma de BarcelonaBarcelonaSpain
  3. 3.Centro de Investigación Biomédica en Red de Salud MentalCIBERSAMMadridSpain
  4. 4.Departamento de Psiquiatria i Medicina LegalUniversitat Autònoma de BarcelonaBarcelonaSpain
  5. 5.Programa de Cognición, Instituto de Fundamentos y Métodos, Facultad de PsicologíaUniversidad de la RepúblicaMontevideoUruguay
  6. 6.Les Corts Centre d’Higiene MentalBarcelonaSpain
  7. 7.Department of Comparative Biomedical Sciences, School of Veterinary MedicineLouisiana State UniversityBaton RougeUSA
  8. 8.The Beckley FoundationOxfordUK
  9. 9.Centre d’Investigació de Medicaments, Servei de Farmacologia ClínicaHospital de la Santa Creu i Sant PauBarcelonaSpain
  10. 10.Department of Pharmacology and TherapeuticsUniversitat Autònoma de Barcelona (UAB)BarcelonaSpain
  11. 11.Human Neuropsychopharmacology GroupSant Pau Institute of Biomedical Research (IIB-Sant Pau)BarcelonaSpain

Personalised recommendations